Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Decreases By 21.1%

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 126,900 shares, a drop of 21.1% from the December 31st total of 160,800 shares. Approximately 7.6% of the company’s shares are short sold. Based on an average trading volume of 2,280,000 shares, the days-to-cover ratio is currently 0.1 days.

180 Life Sciences Trading Up 2.1 %

NASDAQ:ATNF traded up $0.03 during mid-day trading on Thursday, hitting $1.44. The company had a trading volume of 196,136 shares, compared to its average volume of 259,749. 180 Life Sciences has a fifty-two week low of $1.16 and a fifty-two week high of $17.75. The business’s fifty day moving average is $1.91 and its two-hundred day moving average is $2.21.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Saturday, January 18th.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.